Compared · Gene2Rx
Gene2Rx reads more pharmacogenes from a VCF than we do, for less. Here is where the VCF stops.
Gene2Rx is a pharmacogenetics-only service. From a whole-genome VCF it covers 111 medications for $64, in under a minute. On VCF-only pharmacogenomics per dollar it wins, and this page says so first. Its own guide then names the limit that decides the rest.
Where Gene2Rx wins
Breadth from a VCF, per dollar. Its homepage lists a $49 Complete Pharmacogenetics Report covering "111 medications with genetic drug testing" across "all 33 drug classes", with "an additional $15 per report" for a whole-genome VCF, so $64 all in. The homepage counts "27 pharmacogenes"; its own comparison table lists 29 gene symbols. From a VCF alone, our whole-genome report resolves eight pharmacogenes at CPIC star-allele level and refuses the rest, because a naive single-variant call on TPMT, UGT1A1, CYP3A5 or CYP2B6 can be confidently wrong. If a VCF is all you hold and pharmacogenomics is all you want, Gene2Rx gives you more genes for less money.
Speed and a subscription that makes sense. "Get your pharmacogenetics report in under 1 minute after upload", and a $20-a-year Pro tier that regenerates the report as new versions ship. Our whole-genome report takes about a quarter of an hour and its re-analysis subscription is €29 a year.
Plain disclaimers. Every page repeats that "direct-to-consumer genetic data is not clinical grade; use your report only as a conversation starter". We say the same thing in our own words, and we credit a competitor that says it clearly.
Where the two differ
| Gene2Rx | Aimosti | |
|---|---|---|
| Price | $49 Complete report, +$15 for a WGS VCF = $64; $35 psychiatric; $5 starter; Pro $20/year (its homepage) | €89 whole-genome report including VCF pharmacogenomics; €109 Deep Read reads panel; €169 together |
| What it reads | Array exports and "VCF from any provider", GRCh37 or GRCh38; no BAM, CRAM or FASTQ mentioned (its homepage) | Chip exports, VCF, gVCF, and BAM or CRAM for the reads panel |
| Pharmacogenes | "27 pharmacogenes" (homepage) or 29 (its comparison table), 111 medications, CPIC and FDA guidance | 8 from a VCF; 29 from reads to CPIC star-allele resolution, from a pinned CPIC snapshot |
| CYP2D6 copy number | "does not detect copy-number changes such as CYP2D6 gene duplications or deletions, which require raw alignment files" (its Nucleus and Sequencing.com guides) | Called from the reads, duplications, deletions and hybrids included |
| HLA | "does not currently report HLA alleles" (same guides) | HLA-B*57:01 and B*15:02 inferred from tag variants in every report, labelled as inferred; HLA-DQA1/DQB1 typed from reads for celiac risk |
| Coverage | Reads the variant calls in the VCF | Per-gene callability measured from the reads; a gene the reads cannot cover is declined |
| Beyond pharmacogenomics | None; it is a pharmacogenetics report | Clinical findings, carrier status, traits, ancestry and polygenic scores from the same file |
| Where the file goes | Processed in the United States on AWS; report and file kept "unless otherwise requested", opt-out deletes within 24 hours (its privacy policy) | Processed and stored in Finland; deleted after analysis by default; reads deleted when the run finishes |
| Entity | "GENOME ANALYTICS L.L.C." in its terms; no address or governing law published | Aimosti Oy, Finland |
What the reads add, in Gene2Rx's own words
The sentence to read twice is theirs: copy-number changes in CYP2D6 "require raw alignment files". That gene shapes the dosing of common antidepressants, painkillers and tamoxifen, and its duplications, deletions and pseudogene hybrids are exactly what a variant list cannot represent. Deep Read reads them from the BAM or CRAM, and does the same for the other structurally awkward genes in the panel, then measures how much of each gene was actually covered. It ends in a one-page hand-off for a prescriber. Where a VCF can call a gene honestly, we call it from the VCF; where it cannot, we say so instead of printing a diplotype that looks confident.
If you hold only a VCF and want the widest pharmacogene list, buy Gene2Rx. If you hold the reads, the answer to the question its guide raises is the panel here.
Gene2Rx is described from its own public pages as read on 3 September 2026. Prices are quoted as displayed that day, in the currency shown there, and features change. We do not speak for Gene2Rx. If something here is out of date, tell us and we will correct it.
Hold a BAM or CRAM? See what the reads panel returns before you decide.
Other comparisons: Promethease · Genetic Lifehacks · SelfDecode · Sequencing.com · all five